– $ 0.18 EPS expected for Kintara Therapeutics, Inc. (NASDAQ: KTRA) this quarter
Analysts expect Kintara Therapeutics, Inc. (NASDAQ: KTRA) to post earnings of ($ 0.18) per share for the current fiscal quarter, according to Zacks. No analyst has estimated Kintara Therapeutics’ earnings, with the highest estimate of EPS ($ 0.17) and the lowest estimate ($ 0.18). Kintara Therapeutics posted earnings per share of ($ 0.22) in the same quarter of last year, indicating a positive year-over-year growth rate of 18.2%. The company is expected to announce its next quarterly earnings report on Friday, February 11.
According to Zacks, analysts expect Kintara Therapeutics to report annual earnings of ($ 0.71) per share for the current year, with EPS estimates ranging from $ 0.73 to $ 0.68. For the next fiscal year, analysts expect the company to post earnings of ($ 0.67) per share, with EPS estimates ranging from $ 0.79 to $ 0.55. Zacks EPS Averages is an average based on a survey of analysts who provide coverage for Kintara Therapeutics.
Kintara Therapeutics (NASDAQ: KTRA) last released its quarterly earnings data on Monday, November 15. The company reported ($ 0.17) earnings per share for the quarter, missing the consensus estimate of ($ 0.14) by ($ 0.03).
Several research companies have recently weighed in on KTRA. Aegis lowered its price target on Kintara Therapeutics from $ 7.00 to $ 5.00 and set a âbuyâ rating on the stock in a research note on Thursday, September 30. The Maxim Group assumed coverage of Kintara Therapeutics in a research report on Friday, October 8. They issued a “buy” note and a target price of $ 3.00 for the company. Finally, HC Wainwright assumed coverage of Kintara Therapeutics in a research report on Tuesday, September 28. They issued a âbuyâ note and a target price of $ 6.00 for the company.
NASDAQ: KTRA traded up $ 0.01 during trading hours on Friday, reaching $ 0.63. The company’s shares had a trading volume of 754,620 shares, compared to its average volume of 1,245,187. The stock has a fifty-day simple moving average of $ 0.81 and a 200-day simple moving average. $ 1.30. The company has a market cap of $ 30.48 million, a P / E ratio of -0.76 and a beta of 1.67. Kintara Therapeutics has a twelve month low of $ 0.50 and a twelve month high of $ 3.35.
Institutional investors and hedge funds have recently changed their holdings in the company. Vanguard Group Inc. increased its stake in Kintara Therapeutics by 100.3% in the second quarter. Vanguard Group Inc. now owns 1,122,231 shares of the company valued at $ 2,548,000 after purchasing an additional 561,820 shares during the last quarter. Geode Capital Management LLC increased its stake in Kintara Therapeutics by 5.1% in the third quarter. Geode Capital Management LLC now owns 292,064 shares of the company valued at $ 251,000 after purchasing an additional 14,097 shares in the last quarter. State Street Corp increased its stake in Kintara Therapeutics by 688.1% in the second quarter. State Street Corp now owns 107,974 shares of the company valued at $ 245,000 after purchasing an additional 94,274 shares in the last quarter. Citadel Advisors LLC purchased a new stake in Kintara Therapeutics in the first quarter valued at approximately $ 134,000. Finally, Golden State Equity Partners purchased a new stake in Kintara Therapeutics in the second quarter valued at approximately $ 162,000. Institutional investors hold 8.36% of the company’s shares.
Kintara Therapeutics Company Profile
Kintara Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of novel cancer therapies. It focuses on the VAL-083 and REM-001 pipelines. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, California.
Recommended story: How does a reverse stock split work?
Get a Free Copy of Zacks’ Research Report on Kintara Therapeutics (KTRA)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [emailÂ protected]
Should you invest $ 1,000 in Kintara Therapeutics now?
Before you consider Kintara Therapeutics, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly asking their clients to buy now before the broader market takes hold of … and Kintara Therapeutics was not on the list.
While Kintara Therapeutics currently has a âBuyâ rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here